### Guideline Page and Request

**ESOPH-F 4 of 13**

**External Request**
Submission from Genentech, Inc (08/15/19) to consider recommending entrectinib and appropriate NTRK gene fusion testing in the NCCN Guideline for the treatment of NTRK gene fusion-positive esophageal and gastric cancers.

**Internal Request**
In response to the tumor agnostic FDA approval, consider adding the evaluation or tumor testing for NTRK gene fusion and therapies for NTRK-positive tumors (entrectinib or larotrectinib) for patients with recurrent locally advanced, unresectable, or metastatic esophageal or EGJ cancers.

### Panel Discussion/References

Based on a review of the data in the noted references, the panel consensus was to include "Entrectinib or larotrectinib for NTRK gene fusion-positive tumors" as a second-line or subsequent therapy treatment option. This is a category 2A recommendation and was preference stratified under "Other Recommended Regimens".


### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>2</td>
<td>7</td>
<td>8</td>
</tr>
</tbody>
</table>